| scholarly article | Q13442814 |
| P50 | author | Jacob Schlesinger | Q59761359 |
| P2093 | author name string | Walsh EE | |
| Brandriss MW | |||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | encephalitis | Q199615 |
| Dengue virus | Q476209 | ||
| immunization | Q1415366 | ||
| P304 | page(s) | 853-857 | |
| P577 | publication date | 1987-03-01 | |
| P1433 | published in | Journal of General Virology | Q6295245 |
| P1476 | title | Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. | |
| P478 | volume | 68 ( Pt 3) |
| Q56341869 | A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein |
| Q98502795 | A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West Nile virus in mice |
| Q40740394 | An enzyme-linked immunosorbent assay using a chaotropic agent (sodium thiocyanate) for serotype specific reaction between crude dengue viral antigen and anti-dengue mouse antibody |
| Q40504189 | An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model |
| Q27472823 | Antibodies against West Nile Virus Nonstructural Protein NS1 Prevent Lethal Infection through Fc Receptor-Dependent and -Independent Mechanisms |
| Q40067512 | Antibodies against nonstructural protein 1 protect mice from dengue virus-induced mast cell activation |
| Q40685948 | Antibodies against tick-borne encephalitis virus (TBEV) non-structural and structural proteins in human sera and spinal fluid |
| Q42285376 | Antibodies generated by immunization with the NS1 protein of West Nile virus confer partial protection against lethal Japanese encephalitis virus challenge |
| Q27486409 | Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II |
| Q88310300 | Antibody profiling using a recombinant protein-based multiplex ELISA array accelerates recombinant vaccine development: Case study on red sea bream iridovirus as a reverse vaccinology model |
| Q40344535 | Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice |
| Q39002738 | Antibody recognition of the dengue virus proteome and implications for development of vaccines |
| Q40609243 | Antibody to the nonstructural protein NS1 of Japanese encephalitis virus: potential application of mAb-based indirect ELISA to differentiate infection from vaccination |
| Q35616815 | Antigenic structure of flavivirus proteins |
| Q27321668 | Aspects of T Cell-Mediated Immunity Induced in Mice by a DNA Vaccine Based on the Dengue-NS1 Antigen after Challenge by the Intracerebral Route |
| Q33405382 | Autoimmunity in dengue pathogenesis |
| Q35058899 | Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation |
| Q37425963 | Biomarkers in Japanese encephalitis: a review |
| Q114839357 | C-Terminal Region of Dengue Virus Nonstructural Protein 1 Is Involved in Endothelial Cell Cross-Reactivity via Molecular Mimicry |
| Q42981306 | Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells |
| Q27469691 | Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response |
| Q33389831 | Comparison of a dengue-2 virus and its candidate vaccine derivative: Sequence relationships with the flaviviruses and other viruses |
| Q43047045 | Comparison of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice |
| Q42986364 | Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus |
| Q39751336 | Comprehensive mapping of immunodominant and conserved serotype- and group-specific B-cell epitopes of nonstructural protein 1 from dengue virus type 1. |
| Q30361791 | Consultation on dengue vaccines: progress in understanding protection, 26-28 June 2013, Rockville, Maryland. |
| Q26742214 | Contribution of intertwined loop to membrane association revealed by Zika virus full‐length NS1 structure |
| Q35864468 | Cooperation between CD4+ T Cells and Humoral Immunity Is Critical for Protection against Dengue Using a DNA Vaccine Based on the NS1 Antigen |
| Q27489848 | Cross-reactive memory CD4+ T cells alter the CD8+ T-cell response to heterologous secondary dengue virus infections in mice in a sequence-specific manner |
| Q33408300 | Current progress in dengue vaccines |
| Q40499543 | DNA vaccine against the non-structural 1 protein (NS1) of dengue 2 virus |
| Q40468297 | DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice. |
| Q35625045 | DNA vaccines for flaviviruses |
| Q40614639 | Dengue NS1-specific antibody responses: isotype distribution and serotyping in patients with Dengue fever and Dengue hemorrhagic fever |
| Q38834797 | Dengue Virus NS1 Protein Modulates Cellular Energy Metabolism by Increasing Glyceraldehyde-3-Phosphate Dehydrogenase Activity |
| Q92397008 | Dengue infection and advances in dengue vaccines for children |
| Q42996339 | Dengue infection. |
| Q35964754 | Dengue vaccine: priorities and progress |
| Q40140011 | Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity |
| Q115234065 | Dengue virus NS1 protein conveys pro‐inflammatory signals by docking onto high‐density lipoproteins |
| Q40140017 | Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination |
| Q28278881 | Dengue virus life cycle: viral and host factors modulating infectivity |
| Q27489654 | Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody |
| Q56396121 | Dengue virus non-structural protein 1: a pathogenic factor, therapeutic target, and vaccine candidate |
| Q27486631 | Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes |
| Q27486616 | Dengue virus-specific murine T-lymphocyte proliferation: serotype specificity and response to recombinant viral proteins |
| Q27026302 | Dengue viruses - an overview |
| Q24609884 | Dengue: defining protective versus pathologic immunity |
| Q92942083 | Design and production of dengue virus chimeric proteins useful for developing tetravalent vaccines |
| Q42991355 | Detection by ELISA of antibodies to Japanese encephalitis virus nonstructural 1 protein induced in subclinically infected humans |
| Q37597410 | Development and evaluation of an enzyme-linked immunosorbent assay for quantifying antibodies to Japanese encephalitis virus nonstructural 1 protein to detect subclinical infections in vaccinated horses |
| Q24805060 | Development of Dengue virus type 2 replicons capable of prolonged expression in host cells |
| Q35195483 | Development of a recombinant vaccine against Japanese encephalitis |
| Q24797123 | Development of dengue virus replicons expressing HIV-1 gp120 and other heterologous genes: a potential future tool for dual vaccination against dengue virus and HIV |
| Q36322125 | Development of effective therapies against West Nile virus infection |
| Q37460533 | Differential humoral and cellular immunity induced by vaccination using plasmid DNA and protein recombinant expressing the NS3 protein of dengue virus type 3. |
| Q40374118 | Direct random insertion of an influenza virus immunologic determinant into the NS1 glycoprotein of a vaccine flavivirus |
| Q40540169 | Distribution of E and NS1 proteins of TBE virus in mammalian and tick cells |
| Q40477347 | Enhanced immune response by amphotericin B following NS1 protein prime-oral recombinant Salmonella vaccine boost vaccination protects mice from dengue virus challenge. |
| Q34251847 | Epitope reactions can be gauged by relative antibody discriminating specificity (RADS) values supported by deletion, substitution and cysteine bridge formation analyses: potential uses in pathogenesis studies |
| Q40552138 | Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice |
| Q28204656 | Evasion of innate and adaptive immunity by flaviviruses |
| Q40791245 | Evidence that the mature form of the flavivirus nonstructural protein NS1 is a dimer |
| Q42981199 | Expression of MBP-HCV NS1/E2 fusion protein in E. coli and detection of anti-NS1/E2 antibody in type c chronic liver disease |
| Q27486998 | Expression of dengue virus structural proteins and nonstructural protein NS1 by a recombinant vaccinia virus |
| Q40754356 | Expression of the NS1 gene of dengue virus type 2 using vaccinia virus. Dimerisation of the NS1 glycoprotein |
| Q45762595 | Expression of the nonstructural protein NS1 of equine influenza A virus: detection of anti-NS1 antibody in post infection equine sera |
| Q40766953 | Expression of the structural proteins of dengue 2 virus and yellow fever virus by recombinant vaccinia viruses |
| Q36457958 | Expression, purification, and evaluation of diagnostic potential and immunogenicity of a recombinant NS3 protein from all serotypes of dengue virus |
| Q24705181 | Flavivirus NS1 protein in infected host sera enhances viral acquisition by mosquitoes |
| Q35625036 | Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines |
| Q26782367 | Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine |
| Q43048910 | Heterocomplexes of tick-borne encephalitis structural and non-structural proteins |
| Q40308632 | High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model |
| Q34566234 | Human T cell responses to dengue virus antigens. Proliferative responses and interferon gamma production |
| Q58569620 | Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model |
| Q38125045 | Identifying protective dengue vaccines: guide to mastering an empirical process |
| Q37901360 | Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms |
| Q27486871 | Immunization of mice with dengue structural proteins and nonstructural protein NS1 expressed by baculovirus recombinant induces resistance to dengue virus encephalitis |
| Q27486490 | Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis |
| Q27480814 | Immunization with nonstructural proteins promotes functional recovery of alphavirus-infected neurons |
| Q44241050 | Immunogenicity of a Japanese encephalitis DNA vaccine candidate in cynomolgus monkeys |
| Q56000963 | Incorporation of NS1 and prM/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E protein |
| Q34059579 | Induction of a protective response in mice by the dengue virus NS3 protein using DNA vaccines. |
| Q34542855 | Innate and Adaptive Immune Responses Determine Protection against Disseminated Infection by West Nile Encephalitis Virus |
| Q40190331 | Investigating the efficacy of monovalent and tetravalent dengue vaccine formulations against DENV-4 challenge in AG129 mice |
| Q42985119 | Japanese encephalitis virus fusion protein with protein A expressed in Escherichia coli confers protective immunity in mice |
| Q41704328 | Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection |
| Q36441519 | Japanese encephalitis: development of new candidate vaccines |
| Q37336555 | Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge |
| Q42989189 | Maturation of Japanese encephalitis virus glycoproteins produced by infected mammalian and mosquito cells |
| Q27486619 | Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis |
| Q27485490 | Monoclonal Antibodies That Bind to Common Epitopes on the Dengue Virus Type 2 Nonstructural-1 and Envelope Glycoproteins Display Weak Neutralizing Activity and Differentiated Responses to Virulent Strains: Implications for Pathogenesis and Vaccines |
| Q27480738 | Multiple specificities in the murine CD4+ and CD8+ T-cell response to dengue virus |
| Q33390190 | NS 1 gene sequences from eight dengue-2 viruses and their evolutionary relationships with other dengue-2 viruses |
| Q33361468 | NS1: A corner piece in the dengue pathogenesis puzzle? |
| Q35228879 | New Approaches to Flavivirus Vaccine Development |
| Q24289099 | Nonstructural Protein 1-Specific Immunoglobulin M and G Antibody Capture Enzyme-Linked Immunosorbent Assays in Diagnosis of Flaviviral Infections in Humans |
| Q40266564 | Optimization of Dengue-3 recombinant NS1 protein expression in E. coli and in vitro refolding for diagnostic applications |
| Q38636217 | Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development |
| Q27860978 | Pathogenesis of dengue: challenges to molecular biology |
| Q35613343 | Pathogenesis of flavivirus encephalitis |
| Q35206380 | Phenotypic characterization of patient dengue virus isolates in BALB/c mice differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome |
| Q40078229 | Plant-produced anti-dengue virus monoclonal antibodies exhibit reduced antibody-dependent enhancement of infection activity. |
| Q38998237 | Precise location of sequential dengue virus subcomplex and complex B cell epitopes on the nonstructural-1 glycoprotein |
| Q42986334 | Preparation of Japanese encephalitis virus nonstructural protein NS1 obtained from culture fluid of JEV-infected Vero cells |
| Q41161256 | Presentation of the hydrophilic domains of hepatitis C viral E2 envelope glycoprotein on hepatitis B surface antigen particles |
| Q40576750 | Production of the baculovirus-expressed dengue virus glycoprotein NS1 can be improved dramatically with optimised regimes for fed-batch cultures and the addition of the insect moulting hormone, 20-Hydroxyecdysone |
| Q36825107 | Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach |
| Q27489893 | Progress on the development of therapeutics against West Nile virus |
| Q40568574 | Prolonged presence of effector-memory CD8 T cells in the central nervous system after dengue virus encephalitis |
| Q27486615 | Proper processing of dengue virus nonstructural glycoprotein NS1 requires the N-terminal hydrophobic signal sequence and the downstream nonstructural protein NS2a |
| Q40500253 | Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence |
| Q33414156 | Protection against dengue virus infection in mice by administration of antibodies against modified nonstructural protein 1. |
| Q40302309 | Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant. |
| Q40740498 | Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies |
| Q40622821 | Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice |
| Q39636134 | Ratios of subclinical to clinical Japanese encephalitis (JE) virus infections in vaccinated populations: evaluation of an inactivated JE vaccine by comparing the ratios with those in unvaccinated populations |
| Q92859173 | Recent advances in understanding dengue |
| Q35976650 | Recombinant Dengue 2 Virus NS3 Helicase Protein Enhances Antibody and T-Cell Response of Purified Inactivated Vaccine |
| Q40736079 | Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis |
| Q45751224 | Retrospective study of Western blot profiles in immune sera of natural dengue virus infections |
| Q40264220 | Secreted expression and purification of dengue 2 virus full-length nonstructural glycoprotein NS1 in Pichia pastoris |
| Q43047722 | Sequence of the NS 1 gene of the K 23 isolate of tick-borne encephalitis virus and identification of conserved motifs |
| Q34978832 | Sequence of the dengue virus type 2 (strain PR-159) NS1 gene and comparison with its vaccine derivative |
| Q40781302 | Serologically defined linear epitopes in the envelope protein of dengue 2 (Jamaica strain 1409). |
| Q27486168 | Structure and organization of the hepatitis C virus genome isolated from human carriers |
| Q40299477 | Structure of the dengue virus glycoprotein non-structural protein 1 by electron microscopy and single-particle analysis |
| Q66679253 | T Cell Responses Induced by DNA Vaccines Based on the DENV2 E and NS1 Proteins in Mice: Importance in Protection and Immunodominant Epitope Identification |
| Q34855420 | Targeting the non-structural protein 1 from dengue virus to a dendritic cell population confers protective immunity to lethal virus challenge |
| Q66679100 | The Dual Role of the Antibody Response Against the Flavivirus Non-structural Protein 1 (NS1) in Protection and Immuno-Pathogenesis |
| Q59356038 | The Good, the Bad, and the Shocking: The Multiple Roles of Dengue Virus Nonstructural Protein 1 in Protection and Pathogenesis |
| Q33952146 | The NS1 glycoprotein can generate dramatic antibody-enhanced dengue viral replication in normal out-bred mice resulting in lethal multi-organ disease |
| Q38179175 | The dengue virus non-structural 1 protein: risks and benefits |
| Q38812747 | The dengue virus non-structural protein 1 (NS1) is secreted efficiently from infected mosquito cells. |
| Q40045509 | The dengue virus non-structural protein 1 (NS1) is secreted from infected mosquito cells via a non-classical caveolin-1-dependent pathway. |
| Q24616798 | The dengue viruses |
| Q38092510 | The flavivirus NS1 protein: molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker |
| Q40752408 | The sensitivity of cell-associated dengue virus proteins to trypsin and the detection of trypsin-resistant fragments of the nonstructural glycoprotein NS1. |
| Q40039016 | Therapeutic Effects of Monoclonal Antibody against Dengue Virus NS1 in a STAT1 Knockout Mouse Model of Dengue Infection |
| Q89719749 | Tick-Borne Encephalitis Virus Vaccines Contain Non-Structural Protein 1 Antigen and may Elicit NS1-Specific Antibody Responses in Vaccinated Individuals |
| Q63246368 | Tracking dengue virus type 1 genetic diversity during lineage replacement in an hyperendemic area in Colombia |
| Q28077521 | Vaccines and immunization strategies for dengue prevention |
| Q40303277 | Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement |
Search more.